The endogenous peptide GPR15L shapes the intestinal microbiota to counteract colitis.

Saved in:
Bibliographic Details
Title: The endogenous peptide GPR15L shapes the intestinal microbiota to counteract colitis.
Authors: Leggio M; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Schramm S; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Dietz L; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Ocón B; Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine and Palo Alto Veterans Medical Center, Stanford, Palo Alto, California, USA., Wirtz S; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Puertolas Balint F; Department of Molecular Biology, Umeå University, Umeå, Sweden.; Laboratory for Molecular Infection Medicine Sweden (MIMS) and Umeå Center for Microbial Research (UCMR), Umeå University, Umeå, Sweden., Yilmaz B; Maurice Müller Laboratories, Department for Biomedical Research, University of Bern, Bern, Switzerland., Petzold J; Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Liu LJ; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Dedden M; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Ekici A; Institute of Human Genetics, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Meng X; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Bingham D; Department of Pathology, Stanford University School of Medicine, Stanford, California, USA., Ullrich KA; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Heltmann-Meyer S; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Günther C; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Hildner K; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Atreya R; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Atreya I; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Müller TM; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Gerlach RG; Institute of Clinical Microbiology, Immunology and Hygiene, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany., Schroeder BO; Department of Molecular Biology, Umeå University, Umeå, Sweden.; Laboratory for Molecular Infection Medicine Sweden (MIMS) and Umeå Center for Microbial Research (UCMR), Umeå University, Umeå, Sweden., Macpherson A; Maurice Müller Laboratories, Department for Biomedical Research, University of Bern, Bern, Switzerland., Butcher EC; Laboratory of Immunology and Vascular Biology, Department of Pathology, Stanford University School of Medicine and Palo Alto Veterans Medical Center, Stanford, Palo Alto, California, USA., Neurath MF; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany., Zundler S; Department of Medicine 1, University Hospital Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany sebastian.zundler@uk-erlangen.de.; Deutsches Zentrum Immuntherapie, University Hospital Erlangen, Erlangen, Germany.
Corporate Authors: TRR241 IBDome Consortium, TRR241 IBCome Consortium
Source: Gut [Gut] 2026 Jun 25. Date of Electronic Publication: 2026 Jun 25.
Publication Type: Journal Article
Journal Info: Publisher: British Medical Assn Country of Publication: England NLM ID: 2985108R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-3288 (Electronic) Linking ISSN: 00175749 NLM ISO Abbreviation: Gut Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1468-3288
DOI:10.1136/gutjnl-2025-337619